6533b860fe1ef96bd12c3168

RESEARCH PRODUCT

Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma.

Michele ReibaldiRosario CaltabianoAndrea RussoArgyrios ChronopoulosMatteo FallicoTeresio AvitabileVincenza BonfiglioCorrado SpatolaAntonio Longo

subject

MaleIntraocular pressureFovea CentralisVisual acuitygenetic structuresmedicine.medical_treatmentBrachytherapyVisual AcuityIntravitreal aflibercept; Plaque brachytherapy; Radiation maculopathy; Aged; Brachytherapy; Choroid Neoplasms; Dose-Response Relationship Drug; Dose-Response Relationship Radiation; Female; Fluorescein Angiography; Follow-Up Studies; Fovea Centralis; Fundus Oculi; Humans; Intravitreal Injections; Macular Edema; Male; Melanoma; Middle Aged; Prospective Studies; Receptors Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Ruthenium Radioisotopes; Tomography Optical Coherence; Treatment Outcome; Visual Acuity0302 clinical medicineEndophthalmitisReceptorsProspective StudiesFluorescein AngiographyTomographyMelanomaAfliberceptRadiationmedicine.diagnostic_testVascular Endothelial Growth FactorChoroid NeoplasmsMiddle AgedFluorescein angiographySensory SystemsTreatment OutcomeIntravitreal InjectionsFemaleIntravitreal aflibercept; Plaque brachytherapy; Radiation maculopathy; Aged; Brachytherapy; Choroid Neoplasms; Dose-Response Relationship; Drug; Dose-Response Relationship; Radiation; Female; Fluorescein Angiography; Follow-Up Studies; Fovea Centralis; Fundus Oculi; Humans; Intravitreal Injections; Macular Edema; Male; Melanoma; Middle Aged; Prospective Studies; Receptors; Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Ruthenium Radioisotopes; Tomography; Optical Coherence; Treatment Outcome; Visual Acuitymedicine.symptomIntravitreal afliberceptDrugRuthenium RadioisotopesTomography Optical CoherenceHumanmedicine.drugmedicine.medical_specialtyFundus OculiRecombinant Fusion ProteinsRuthenium RadioisotopeMacular EdemaFollow-Up StudieDose-Response Relationship03 medical and health sciencesCellular and Molecular NeuroscienceRadiation maculopathyOphthalmologymedicineHumansMacular edemaAgedFovea CentraliDose-Response Relationship Drugbusiness.industryPlaque radiotherapyIntravitreal InjectionPlaque brachytherapyDose-Response Relationship Radiationmedicine.diseaseeye diseasesProspective StudieOphthalmologyReceptors Vascular Endothelial Growth FactorOptical Coherence030221 ophthalmology & optometryMaculopathysense organsbusinessChoroid Neoplasm030217 neurology & neurosurgeryRecombinant Fusion ProteinFollow-Up Studies

description

Purpose: To assess the efficacy of intravitreal aflibercept in patients suffering from post-radiation macular edema following plaque radiotherapy for choroidal melanoma. Methods: This prospective, interventional case series included patients affected by radiation maculopathy (RM) with macular edema secondary to ruthenium-106 plaque brachytherapy for choroidal melanoma. The effect of intravitreal aflibercept on best-corrected visual acuity (BCVA), central foveal thickness (CFT) detected by spectral domain optical coherence tomography (sd-OCT), and Horgan’s grading scale of RM was evaluated throughout the 24-month follow-up. Intraocular pressure (IOP) and possible complications were also recorded. Results: Nine eyes of 9 patients were included. A mean of 4.4 ± 1.2 injections were given over the 24 months. At the end of follow-up, mean BCVA was significantly improved, from 0.9 ± 0.19 logMAR at baseline to 0.56 ± 0.3 logMAR (P = 0.028), and mean CFT was significantly decreased, from 546 ± 123 μm at baseline to 223 ± 34 μm (P < 0.001). Intravitreal aflibercept lowered baseline maculopathy stage as well. No significant change in IOP values and no complications, such as endophthalmitis, was recorded. Conclusion: Intravitreal aflibercept is an effective treatment for patients with radiation-induced macular edema, allowing functional and anatomical improvements to be achieved with a relatively low number of injections.

10.1007/s00417-019-04347-6https://pubmed.ncbi.nlm.nih.gov/31081526